TELA Bio, Inc. (NASDAQ: TELA) reported Q4 EPS of ($0.23), $0.01 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $17.6 million versus the consensus estimate of $23.17 million.

For earnings history and earnings-related data on TELA Bio, Inc. (TELA) click here.